Literature DB >> 206671

Membranous neuronal and neuroglial inclusions produced by intracerebral injection of Suramin.

S Rees.   

Abstract

A single intracerebral injection of 5 micrometer of the trypanocidal drug Suramin, into the left hemisphere of young rats, resulted in the formation of membranous inclusion bodies within the perikarya and processes of neurones and neuroglia. These inclusion bodies were round or oval in shape and 0.5-3.0 micrometer in their longest diameter. They were bounded by a single trilaminar membrane and contained closely packed membranes in concentric, curved or parallel arrays. The inclusions were distributed throughout the cerebral cortex and underlying hippocampus at the injection site, and in reduced numbers up to 1 mm anteriorly and posteriorly from it. They formed within 22 hr of the injection and had increased in numbers and in the complexity of their arrays 3 days after injection. Within 14 days, the inclusions were markedly reduced in number. As Suramin is known to inhibit lysosomal hydrolases required for the degradation of proteins, glycolipids and mucopolysaccharides, the membranous inclusions could form as a result of the accumulation of these substances within lysosomes. These experiments indicate a possible experimental model for storage diseases. It is hoped that the extension of this paradigm to other enzyme inhibitors will provide a new means of identifying some of the unusual inclusions that can be found in neurones and neuroglia (Rees 1975).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 206671     DOI: 10.1016/0022-510x(78)90164-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

1.  Suramin-induced storage disease. Mucopolysaccharidosis.

Authors:  G Constantopoulos; S Rees; B G Cragg; J A Barranger; R O Brady
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

2.  Abundance of surfactant-like particles reflects mucosal integrity in patients with peptic ulcer disease.

Authors:  R Eliakim; D H Alpers; R Oren; A Fich; K DeSchryver-Kecskemeti
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

3.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Morphological study on the hereditary neurogenic amyotrophic dogs: accumulation of lipid compound-like structures in the lower motor neuron.

Authors:  S Izumo; F Ikuta; A Igata; M Osame; C Yamauchi; S Inada
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

5.  Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.

Authors:  G Constantopoulos; S Rees; B G Cragg; J A Barranger; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.